DCPH News and Press, Deciphera Pharmaceuticals Inc. From 03/18/23

2023-03-18 05:21:53 ET Summary Deciphera has a strong portfolio of investigational kinase inhibitors, including ripretinib, vimseltinib, and DCC-3116, that have demonstrated encouraging preliminary efficacy and safety data in treating various types of cancer. The company has compl...

2023-03-16 17:25:25 ET Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) had risen 13.4% for the week as of late Thursday afternoon, according to data provided by S&P Global Market Intelligence . The company, which focuses on oncology therapies, announced that the Food ...

– Top-line Results Expected in the Fourth Quarter of 2023 – – Phase 1/2 Data Demonstrated Vimseltinib’s Best-in-Class Potential for the Treatment of TGCT – Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on d...

Deciphera Pharmaceuticals, Inc. (DCPH) Q4 2022 Earnings Conference Call February 07, 2023 8:00 AM ET Company Participants Jen Larson – Senior Vice President-Finance and Investor Relations Steve Hoerter – President and Chief Executive Officer Dan Martin &#...

Deciphera Pharmaceuticals press release ( NASDAQ: DCPH ): Q4 GAAP EPS of -$0.60 misses by $0.04 . Revenue of $36.35M (+50.2% Y/Y) beats by $0.47M . Generated Gross Proceeds of Approximately $143.7 Million from Public Offering in January 2023 For further details s...

– Fourth Quarter 2022 Total Revenue of $36.3 Million and Full Year 2022 Revenue of $134.0 Million ; QINLOCK ® Net Product Revenue Increased 44% to $125.5 Million in 2022 Compared to 2021 – – Expects to Complete Enrollment in the MOTION Pivotal...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the fol...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2022 financial results on Tu...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the closing of its underwritten public offering of 7,986,111 shares of its common...

– Second-Line GIST Patients with Mutations in KIT Exon 11 + 17/18 Only Demonstrated Substantial Clinical Benefit from QINLOCK ® but Not Sunitinib – – Company Plans to Initiate the INSIGHT Pivotal Phase 3 Clinical Study in the Second Half of 2023 – ...